Form 4: Pfizer Executive Vice President Douglas Lankler Reports Stock Transactions

Executive Vice President Douglas Lankler reports the earn-out of stock appreciation rights and related transactions involving Pfizer common stock.

Summary

• Douglas Lankler, an Executive Vice President at Pfizer Inc., reported transactions involving Pfizer's common stock on February 22, 2025.
• The transactions included the earn-out of 85,824 stock appreciation rights at a price of $30.17.
• Shares were withheld to satisfy tax obligations (3,334 shares at $26.3) and to cover the exercise price of the stock appreciation rights (76,565 shares at $26.08).
• Following these transactions, Lankler directly owns 152,876 shares of Pfizer common stock and indirectly owns 1,951 shares through a Rule 16b-3 plan.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't convey any particular positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, as required by the SEC. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders and are comparable across all publicly traded companies.
• The transactions reported are typical for executives who receive stock-based compensation.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent routine executive compensation activities.
• The filing provides transparency to shareholders regarding executive stock ownership.

Key Dates